Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China
PLOS One · 2025
DOI: 10.1371/journal.pone.0329464 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Shaohuan Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Science and Technology Major Project, 2022 Pharmaceutical Research Project of Guangxi Pharmaceutical Association Hospital, 2022 Bethune·Quest Pharmaceutical Research Capacity Building Project.
Abstract (Originalsprache)
Objective
To analyze the real-world characteristics and patterns of adverse drug reactions (ADRs) associated with tislelizumab, providing valuable insights for clinical practice.
Methods
We conducted a comprehensive analysis of tislelizumab-related ADR reports within the pharmacovigilance system of Guangxi, China, spanning from 01/04/2021–31/08/2024. Our analysis focused on population characteristics, temporal distribution of ADR occurrences, system organ classes (SOCs) of serious adverse drug reactions (SADRs), profiles of major SOCs, and factors influencing SADRs and blood and lymphatic system disorders (BLSDs).
Results
This study analyzed 507 tislelizumab ADR reports (698 events), including 282 SADRs (356 events), with no deaths reported. Pharmacists were the primary reporters (60.55% of reports). Most patients were aged 46–75 years (77.32%), male (72.58%), and of Han ethnicity (75.54%), and 1.78% (9/507) were of Zhuang ethnicity. A total of 86.19% of ADRs occurred within 30 days of medication. Among the SADRs, there were 83 PTs and 17 SOCs, with the most common SOCs being blood and lymphatic system disorders (15.47%, 108/698), investigations (14.90%, 104/698), hepatobiliary disorders (4.15%, 29/698), and skin and subcutaneous tissue disorders (3.15%, 22/698). Logistic regression analysis showed that chemotherapy was a significant risk factor for SADRs (OR = 4.634, 95%CI: 2.871–7.917, P < 0.001). The risk of BLSDs - related ADRs was 5.545 times higher in the chemotherapy-incorporating group than in the monotherapy group (95%CI: 3.423–8.701, P < 0.001).
Conclusions
Close monitoring, particularly in patients receiving chemotherapy-incorporating regimens, is crucial during the first 30 days post-tislelizumab treatment to manage SADR risks. Proactive measures should be implemented if SADR occur.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First People's Hospital of Yulin, Yulin, Guangxi, China.
- Adverse Drug Reaction Monitoring Office, Yulin Food and Drug Inspection and Testing Center, Yulin, Guangxi, China.
ORCID-Profile: Guangyi Meng
Förderung
- Guangxi Science and Technology Major Project
- 2022 Pharmaceutical Research Project of Guangxi Pharmaceutical Association Hospital
- 2022 Bethune·Quest Pharmaceutical Research Capacity Building Project
Zitieren
APA
Lu, S., Chen, D., Li, Y., Chen, Q., & Meng, G. (2025). Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China. PLOS One. https://doi.org/10.1371/journal.pone.0329464
Vancouver
Lu S, Chen D, Li Y, Chen Q, Meng G. Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China. PLOS One. 2025. doi:10.1371/journal.pone.0329464
BibTeX
@article{Lu2025,
author = {Lu, Shaohuan and Chen, Dajian and Li, Yang and Chen, Qianxi and Meng, Guangyi},
title = {Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0329464}
}
EUVIMED